Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple Myeloma
Authors not listed
UNC Lineberger Comprehensive Cancer Center · 2023
Abstract
This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to multiple myeloma that has returned or has not responded to prior treatment. The study will specifically investigate the impact of administering lower-than-standard doses of pomalidomide and dexamethasone. Using lower doses of pomalidomide and dexamethasone in this setting has not been approved by the Food and Drug Administration (FDA).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-20 MST
Cite this
APA
Anonymous. (2023). Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple Myeloma. <em>UNC Lineberger Comprehensive Cancer Center</em>. https://clinicaltrials.gov/study/NCT05911321
Vancouver
Anonymous. Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple Myeloma. UNC Lineberger Comprehensive Cancer Center. 2023.
BibTeX
@misc{anon2023Studyo,
title = {Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple Myeloma},
author = {Anonymous},
journal = {UNC Lineberger Comprehensive Cancer Center},
year = {2023},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
UNC Lineberger Comprehensive Cancer Center 2022
Open access · US-GOV
Phase 2 Study of Isatuximab Plus Lenalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Newly Diagnosed Multiple Myeloma
Beijing Immunochina Medical Science & Technology Co., Ltd. 2020
Open access · US-GOV
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
Washington University School of Medicine 2012
Open access · US-GOV
Pilot Study of Geriatric Assessments in Senior Adults With Multiple Myeloma
University Hospital, Caen 2019
Open access · US-GOV
A Multicentre Open-label Phase II Study of Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma
Archives of Gerontology and Geriatrics 2008
Preprint · OA
Biomarkers of aging and falling: The Beaver Dam eye study
KTO Karatay University 2026
Open access · US-GOV